文献速递神经肌肉病

依达拉奉在特定早期肌萎缩侧索硬化患者中的安全性与有效性:一项随机双盲安慰剂对照试验

Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial.
PubMed 文献 · Lancet Neurol · 2017-05-15

这项3期随机双盲安慰剂对照试验纳入137例符合特定标准的早期ALS患者,依达拉奉组68例和安慰剂组66例纳入主要疗效分析。

要点

  • 依达拉奉组24周ALSFRS-R评分下降显著小于安慰剂组。
  • 疗效仅见于符合特定入组标准的早期ALS患者亚组。
  • 两组治疗中出现的不良事件发生率均为84%。

核心结论

  • 在符合特定入组标准的早期ALS患者中,依达拉奉较安慰剂显著减缓ALSFRS-R评分的下降。
  • 没有迹象表明依达拉奉对不符合这些标准的更广泛ALS人群有效。

研究设计与样本

  • 3期随机双盲平行组安慰剂对照试验,在日本31家医院开展。
  • 纳入20-75岁、日本ALS严重度分级1或2级、ALSFRS-R所有12项至少2分、用力肺活量≥80%、修订El Escorial标准确诊或 probable ALS、病程≤2年且观察期ALSFRS-R下降1-4分的患者。
  • 137例完成观察期后随机1:1接受依达拉奉60 mg静脉给药或生理盐水安慰剂,共6个周期(每周期4周,用药2周停药2周),总治疗24周。
  • 主要疗效分析纳入依达拉奉组68例和安慰剂组66例。

主要发现

  • 治疗中出现的不良事件:依达拉奉组58例(84%),安慰剂组57例(84%)。
  • 严重不良事件:依达拉奉组11例(16%),安慰剂组16例(24%)。
  • 导致退出的不良事件:依达拉奉组1例(1%,吞咽困难),安慰剂组4例(6%,呼吸困难1例、呼吸障碍2例、皮疹1例)。

关键数值与推荐

  • 入组标准包括ALSFRS-R所有12项至少2分、用力肺活量≥80%、修订El Escorial标准确诊或 probable ALS、病程≤2年。
  • 随机前12周观察期内ALSFRS-R评分下降1-4分。
  • 依达拉奉剂量为60 mg静脉给药,6个周期共24周。

临床怎么用

  • 对于符合本研究入组标准的早期ALS患者,可考虑使用依达拉奉治疗。
  • 不符合这些标准的ALS患者不应期望从依达拉奉治疗中获益。

局限性

  • 研究仅纳入符合特定入组标准的早期ALS患者,结果不能外推至更广泛ALS人群。
  • 缺失值采用LOCF法填补,可能影响结果解释。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In a previous phase 3 study in patients with amyotrophic lateral sclerosis (ALS), edaravone did not show a significant difference in the Revised ALS Functional Rating Scale (ALSFRS-R) score compared with placebo. Post-hoc analysis of these data revealed that patients in an early stage with definite or probable diagnosis of ALS, defined by the revised El Escorial criteria, who met a select set of inclusion criteria showed a greater magnitude of effect than did the full study population. We aimed to substantiate this post-hoc result and assess safety and efficacy of edaravone in a phase 3 trial that focused on patients with early stage ALS who met the post-hoc analysis inclusion criteria. METHODS: In this phase 3, randomised, double-blind, parallel-group study, patients aged 20-75 years with ALS of grade 1 or 2 in the Japan ALS Severity Classification, scores of at least 2 points on all 12 items of ALSFRS-R, forced vital capacity of 80% or more, definite or probable ALS according to the revised El Escorial criteria, and disease duration of 2 years or less were recruited from 31 hospitals in Japan. Eligible patients also had a decrease of 1-4 points in the ALSFRS-R score during a 12-week observation period before randomisation. Patients meeting all criteria were then randomly assigned 1:1 to receive 60 mg intravenous edaravone or intravenous saline placebo for 6 cycles (4 weeks per cycle with 2 weeks on, 2 weeks off) for a total treatment duration of 24 weeks. In cycle 1, the study drug or placebo was administered once per day for 14 days within a 14 day period, followed by the drug-free period. In cycle 2 and thereafter, the study drug or placebo was administered for 10 days within a 14 day period, followed by a 2 week drug-free period. Participants and investigators, including those assessing outcomes, were masked to treatment allocation. The primary efficacy outcome was the change in ALSFRS-R score from the baseline to 24 weeks (or at discontinuation if this was after the third cycle) after randomisation. The primary outcome was assessed in all patients who had received at least one treatment infusion, had at least one assessment post-baseline, and reached the end of cycle 3. For patients with missing values at the end of cycle 6, data were imputed by the last observation carried forward (LOCF) method, provided the patients had completed at least cycle 3. Safety was assessed in all patients who had received at least one treatment infusion and had at least one assessment post-baseline. This trial is registered with ClinicalTrials.gov, NCT01492686. FINDINGS: Between Nov 28, 2011, and Sept 3, 2014, we screened 213 patients, and enrolled 192 as potential participants. Of these, 137 patients completed the observation period: 69 were randomly assigned to receive edaravone, and 68 were randomly assigned to receive placebo. 68 patients taking edaravone and 66 taking placebo were included in the primary efficacy analysis. For the primary outcome, the change in ALSFRS-R score was -5·01 (SE 0·64) in the edavarone group and -7·50 (0·66) in the placebo group. The least-squares mean difference between groups was 2·49 (SE 0·76, 95% CI 0·99-3·98; p=0·0013) in favour of edaravone. Treatment-emergent adverse events were reported in 58 (84%) patients receiving edaravone and 57 (84%) patients receiving placebo. 11 (16%) patients taking edaravone and 16 (24%) taking placebo had serious adverse events, and one (1%) patient receiving edaravone and four (6%) patients receiving placebo had adverse events (one dysphagia in edaravone group and one dyspnoea, two respiratory disorder, and one rash in the placebo group) that led to withdrawal. INTERPRETATION: Edaravone showed efficacy in a small subset of people with ALS who met criteria identified in post-hoc analysis of a previous phase 3 study, showing a significantly smaller decline of ALSFRS-R score compared with placebo. There is no indication that edaravone might be effective in a wider population of patients with ALS who do not meet the criteria. FUNDING: Mitsubishi Tanabe Pharma Corporation.

来源:Lancet Neurol,查看原文。版权归原作者所有。

引用

  1. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2017. PMID: 28522181. doi:10.1016/S1474-4422(17)30115-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。